In this study, topical latanoprost acid applied daily for 6 months increased hair count and improved trichoscopic markers among women with hair loss, suggesting its potential for treating female androgenetic alopecia, particularly at a 0.05% concentration.
July 2026 in “Pharmacological Reports” In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.
November 2024 in “Postępy Biochemii” This article highlights the potential for latanoprost acid, a metabolite of the glaucoma medication latanoprost, to serve as an effective alternative to current treatments for androgenetic alopecia, such as minoxidil and finasteride, facilitating a faster development process for related drugs.
3 citations
,
August 2021 in “Clinics in Dermatology” This review discusses various treatments for hair loss, such as topical agents, oral minoxidil, and laser therapies, but reports no new clinical results; debates on issues like post-finasteride syndrome are also covered.
July 2026 in “Health Science Reports” This study evaluated the efficacy and safety of microneedling combined with mesotherapy for androgenic alopecia and found that combination protocols, particularly those including both finasteride and latanoprost, showed the highest efficacy, especially among women and younger participants.